National rates of initiation and intensification of antidiabetic therapy among patients with commercial insurance | diabetes.medicinematters.com

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

05-24-2018 | Medications | Article

National rates of initiation and intensification of antidiabetic therapy among patients with commercial insurance

Gilstrap LG et al. Diabetes Care 2018. doi: 10.2337/dc17-2585

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

https://doi.org/10.2337/dc17-2585

Home
ADA 2022
Adis Journal Club
In focus
Browse topics
- Cardiovascular disorders
- Chronic kidney disease
- Diabetes devices & technology
- GLP-1 receptor agonists
- Hyperglycemia
- Hypoglycemia
- Obesity, diet, & lifestyle interventions
- SGLT2 inhibitors
- Type 1 diabetes
- Type 2 diabetes
- Browse all topics
About us

Version: 0.2002.0

Medicine Matters Diabetes

National rates of initiation and intensification of antidiabetic therapy among patients with commercial insurance

New additions to the Adis Journal Club

ADA 2022 coverage